Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocular Therapeutix, Inc. on September 21, 2017. The filing discloses the appointment of a new Chief Financial Officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $380,000 annually.
- Target Bonus: 40% of annual base salary.
- Equity Grant: Option to purchase 125,000 shares of common stock.
Material Changes
The primary material change is the leadership transition in the finance department effective September 25, 2017:
- Appointment: Donald Notman appointed as Chief Financial Officer.
- Departure: George Migausky ceases to serve as interim Chief Financial Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance or market outlook. Key contractual terms and potential liabilities include:
- Severance (No Cause/Good Reason): 12 months of base salary and 12 months of health insurance continuation.
- Severance (Post-Change in Control): 18 months of base salary, 1.5x target bonus, full acceleration of equity vesting, and 18 months of health insurance.
- Indemnification: The Company may be required to indemnify Mr. Notman for legal expenses, judgments, fines, and settlements arising from his service as an officer.
Investor Verification Checklist
- Verify the closing stock price on October 2, 2017, to determine the exercise price of the 125,000 share option grant.
- Review the Company's cash position to assess the impact of the new executive compensation package on liquidity.
- Confirm the vesting schedule details (25% at one year, remainder monthly) in the full employment agreement (Exhibit 10.1).
- Monitor future filings for any changes to the interim CFO role or additional executive appointments.